Skip to main content
. Author manuscript; available in PMC: 2013 Jul 1.
Published in final edited form as: J Neurochem. 2012 Jun 7;122(2):308–320. doi: 10.1111/j.1471-4159.2012.07790.x

Figure 7.

Figure 7

Hyperdopamine induced by GBR12909 decreases both surface and intracellular GABAA β2/3 subunit proteins in the PFC and the GSK-3β inhibitor blocks the effect of DA. A, Left panel, representative blots showing the protein levels of GABAA β2/3 and actin after systemic administration of vehicle or GBR12909 or coinjection of GBR12909 and the GSK-3 β inhibitor TDZD. Right panel, quantification of the total GABAA β2/3 protein levels relative to the controls (n = 6, **p < 0.05). B, Left panel, BS3 cross-linking analysis of surface and intracellular GABAA β2/3 proteins after systemic administration of vehicle or GBR12909 or coinjection of GBR12909 and the GSK-3β inhibitor TDZD. Right panel, quantification of surface and intracellular GABAA β2/3 indicated a significant reduction of surface protein level and a slightly higher but not significant level of intracellular protein.